For both induction and maintenance therapy, subcutaneous guselkumab significantly improves clinical outcomes in patients with ...

Pegsunercept seems to be safe and efficacious at an 800 µg/kg dose; however, further dose-finding studies are warranted, as higher dosages or more frequent dosing might improve response rates ...

For patients with active lupus nephritis, obinutuzumab, a humanized type II anti-CD20 monoclonal antibody plus standard ...